Laboratory practices for the diagnosis and management of mucormycosis in France, 2024
- PMID: 39577076
- DOI: 10.1016/j.mycmed.2024.101520
Laboratory practices for the diagnosis and management of mucormycosis in France, 2024
Abstract
This study investigates the diagnostic practices for mucormycosis among 30 French University Hospital mycology laboratories, in 2024. All laboratories perform both direct examination and culture, with fluorescent brighteners being the most commonly used method for direct examination. While 77 % of the participating laboratories routinely identify Mucorales to the species level, with 70 % having adopted Mucorales-specific quantitative PCR, primarily for the diagnosis of invasive fungal infections. Antifungal susceptibility testing practices varied between centers, with 36.7 % of laboratories consistently performing these tests, primarily using gradient concentration strips. Amphotericin B, posaconazole, and isavuconazole were the most frequently tested antifungals. These findings highlight variations in laboratory practices and emphasize the importance of establishing uniform diagnostic and susceptibility testing methods to optimize mucormycosis management.
Keywords: Laboratory practice; Mucorales; Mucormycosis.
Copyright © 2024 SFMM. Published by Elsevier Masson SAS. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Eric Dannaoui has received research grants from Biomérieux: travel grants from Gilead, Mundipharma, and Pfizer; speaker's fee from Mundipharma, Pfizer, and Gilead. Kévin Brunet has received travel grants from Pfizer and Gilead and speaker's fee from Gilead. Laurence Millon has received travel grants from Gilead and Pfizer; speaker's fee from Gilead and Pfizer. Marjorie Cornu received travel grants and speaker's fee from Gilead and Pfizer. The other authors have no conflicts of interest to disclose.
Similar articles
-
Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.Ann Pharmacother. 2016 Sep;50(9):747-57. doi: 10.1177/1060028016655425. Epub 2016 Jun 15. Ann Pharmacother. 2016. PMID: 27307416 Review.
-
Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species.Antimicrob Agents Chemother. 2015 Dec;59(12):7882-7. doi: 10.1128/AAC.02107-15. Epub 2015 Oct 5. Antimicrob Agents Chemother. 2015. PMID: 26438489 Free PMC article.
-
Evaluation of the Gradient Concentration Strip Method for Antifungal Susceptibility Testing of Isavuconazole and Comparators for Mucorales Species.Antimicrob Agents Chemother. 2019 Sep 23;63(10):e00838-19. doi: 10.1128/AAC.00838-19. Print 2019 Oct. Antimicrob Agents Chemother. 2019. PMID: 31358578 Free PMC article.
-
Galleria mellonella as a model system to study virulence potential of mucormycetes and evaluation of antifungal treatment.Med Mycol. 2019 Apr 1;57(3):351-362. doi: 10.1093/mmy/myy042. Med Mycol. 2019. PMID: 29924357 Free PMC article.
-
Mucormycosis: New Developments into a Persistently Devastating Infection.Semin Respir Crit Care Med. 2015 Oct;36(5):692-705. doi: 10.1055/s-0035-1562896. Epub 2015 Sep 23. Semin Respir Crit Care Med. 2015. PMID: 26398536 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources